Company profile
TJ Biopharma Co., Ltd.
Privately held: no public share price (Private Chinese biopharma (founded 2019, Hangzhou GMP facility) developing TJ202/felzartamab in Greater China (licensed from Biogen, April 2026 agreement); Series C-funded (CNY 500M in 2024, ~CNY 600M in 2025), no IPO found. Source: https://www.tjbio.com/en/news/12885 and https://investors.biogen.com/news-releases/news-release-details/biogen-enters-agreement-tj-biopharma-felzartamab-assets-greater Sources: https://clinicaltrials.gov/study/NCT03860038 Entity resolved by asset-pipeline-v2.)
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | CD38Monoclonal antibody | Multiple MyelomaSystemic Lupus Erythematosus | |
| Phase 3 | CD73Monoclonal antibody | Non-Small Cell Lung Cancer |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.